AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16332728 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner with special interest service
Number of subjects: 556
Study 16332728 — intervention group
Group type: COMPARATOR
Intervention: Hospital outpatient care
Number of subjects: 556
Study 12475841 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mL (5 mg) terbutaline + 2 mL of 3% saline solution (group 2)
Number of subjects: 65
Study 12475841 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mL (5 mg) terbutaline + 2 mL of 0.9% saline solution (group 1)
Number of subjects: 65
Study 9804214 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low dose r-HFSH (group A)
Number of subjects: 103
Study 9804214 — intervention group
Group type: COMPARATOR
Intervention: Conventional r-HFSH (group B)
Number of subjects: 103
Study 7593449 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg, twice daily)
Number of subjects: 7
Study 7593449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7593449 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 7
Study 2180831 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO‐5 (5.0 g/100 ml carbohydrate solution)
Number of subjects: 8
Study 2180831 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO‐6 (6.0 g/100 ml carbohydrate solution)
Number of subjects: 8
Study 2180831 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO‐7.5 (7.5 g/100 ml carbohydrate solution)
Number of subjects: 8
Study 2180831 — intervention group
Group type: COMPARATOR
Intervention: Water placebo (WP)
Number of subjects: 8
Study 6990215 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (300 mg twice a day)
Number of subjects: 0
Study 6990215 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg twice a day)
Number of subjects: 0
Study 6990215 — intervention group
Group type: COMPARATOR
Intervention: Hydrallazine (50 mg twice a day)
Number of subjects: 0
Study 6990215 — intervention group
Group type: COMPARATOR
Intervention: Hydrallazine plus Propranolol
Number of subjects: 0
Study 30668636 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-based reactive balance training
Number of subjects: 35
Study 30668636 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi training
Number of subjects: 35
Study 28121710 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 0
Study 28121710 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 0
Study 25660822 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei F19 bid for three days/week for six months
Number of subjects: 100
Study 25660822 — intervention group
Group type: COMPARATOR
Intervention: Placebo bid for three days/week for six months
Number of subjects: 100
Study 25660822 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei F19 bid for three days/week for three months and placebo bid for three days/week for the following three months
Number of subjects: 100
Study 25660822 — intervention group
Group type: COMPARATOR
Intervention: Placebo bid for three days/week for three months and Lactobacillus paracasei F19 bid for three days/week for the following three months
Number of subjects: 100
Study 23295853 — intervention group
Group type: EXPERIMENTAL
Intervention: eicosapentaenoic acid + γ‐linolenic acid
Number of subjects: 26
Study 23295853 — intervention group
Group type: COMPARATOR
Intervention: standard pediatric enteral formula
Number of subjects: 26
Study 20850878 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise with moderate‐intensity: 3 metabolic equivalents (3METs), 3 times per week for 12 weeks
Number of subjects: 31
Study 20850878 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise prescription)
Number of subjects: 31
Study 19584700 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HSV-2 coinfected men
Number of subjects: 232
Study 19584700 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with HIV alone
Number of subjects: 232
Study 19584700 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with HSV-2 alone
Number of subjects: 232
Study 19584700 — intervention group
Group type: COMPARATOR
Intervention: HIV/HSV-2 uninfected men
Number of subjects: 232
Study 19584700 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with HIV/HSV-2 coinfection
Number of subjects: 232
Study 17098137 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial epsilon measurement from right endocardial layer (RE)
Number of subjects: 30
Study 17098137 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial epsilon measurement from left endocardial layer (LE)
Number of subjects: 30
Study 17098137 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial epsilon measurement from middle layer of septum
Number of subjects: 30
Study 17098137 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain rate (SR) measurement from left endocardial layer (LE)
Number of subjects: 30
Study 17098137 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain rate (SR) measurement from right endocardial layer (RE)
Number of subjects: 30
Study 17098137 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain rate (SR) measurement from middle layer of septum
Number of subjects: 30
Study 17098137 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal epsilon measurement for right ventricle
Number of subjects: 30
Study 17098137 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular radial epsilon measurement
Number of subjects: 30
Study 17098137 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular strain rate (SR) measurement
Number of subjects: 30
Study 14716777 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (vitamin E) 2000 international units per day for 1 year
Number of subjects: 29
Study 14716777 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 29
Study 11716166 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP treatment (n=33)
Number of subjects: 63
Study 11716166 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 63
Study 9594761 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 79
Study 9594761 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 79
Study 9594761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 7926290 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-resistant group (SI: 0.31 +/‐ 0.06 x 10(‐4) min‐1.pmol/l‐1)
Number of subjects: 30
Study 7926290 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-sensitive group (SI: 0.92 +/‐ 0.11 x 10(‐4) min‐1.pmol/l‐1)
Number of subjects: 30
Study 7926290 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 30
Study 7926290 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-resistant group
Number of subjects: 30
Study 7926290 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-sensitive group
Number of subjects: 30
Study 2686428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 200 mg every 12 hours
Number of subjects: 43
Study 2686428 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime, 2 g every eight hours
Number of subjects: 43
Study 4933135 — intervention group
Group type: EXPERIMENTAL
Intervention: Deglycyrrhizinated liquorice (Caved-S)
Number of subjects: 47
Study 4933135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31087047 — intervention group
Group type: EXPERIMENTAL
Intervention: Community treatment orders
Number of subjects: 333
Study 31327085 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) aid
Number of subjects: 189
Study 31327085 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard protocols)
Number of subjects: 189
Study 28842574 — intervention group
Group type: EXPERIMENTAL
Intervention: CellCollector CTC detection in GGNs group
Number of subjects: 66
Study 28842574 — intervention group
Group type: EXPERIMENTAL
Intervention: CellCollector CTC detection in lung cancer group
Number of subjects: 66
Study 28842574 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 66
Study 25203157 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2,000 IU/day for 12 weeks)
Number of subjects: 53
Study 25203157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 25203157 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 53
Study 24139766 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoker-to-smoker (S2S) messages
Number of subjects: 39
Study 24139766 — intervention group
Group type: COMPARATOR
Intervention: Expert messages
Number of subjects: 39
Study 21119031 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2-targeted agents (trastuzumab and lapatinib) with standard treatment (taxanes, anthracyclines, capecitabine, anastrozole, letrozole)
Number of subjects: 1848
Study 19912135 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy plus 0.05% isotonic ICG‐assisted ILM peeling
Number of subjects: 78
Study 19912135 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy plus 0.15% trypan blue (TB)‐assisted ILM peeling
Number of subjects: 78
Study 19912135 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy alone without instrumental retinal surface contact (non‐peeling)
Number of subjects: 78
Study 19912135 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated macular hole surgery
Number of subjects: 78
Study 19912135 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphological studies with contrast‐enhanced OCT
Number of subjects: 78
Study 19912135 — intervention group
Group type: EXPERIMENTAL
Intervention: ILM peeling and intraoperative dyes
Number of subjects: 78
Study 19912135 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% intraoperative isotonic ICG with short exposure time
Number of subjects: 78
Study 17342789 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQL assessment
Number of subjects: 213
Study 17342789 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQL assessment followed by a structured interview and discussion
Number of subjects: 213
Study 17342789 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 213
Study 15016021 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF(2) dentifrice and mouthrinse
Number of subjects: 80
Study 15016021 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride (NaF) dentifrice and mouthrinse
Number of subjects: 80
Study 11722304 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 398
Study 11722304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study 9417693 — intervention group
Group type: EXPERIMENTAL
Intervention: Gericomplex (ginseng)
Number of subjects: 0
Study 9417693 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 8189774 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail survey
Number of subjects: 100
Study 8189774 — intervention group
Group type: COMPARATOR
Intervention: Telephone survey
Number of subjects: 100
Study 3103245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (3 doses of 1 gram each at induction and 1 and 3 hours later)
Number of subjects: 108
Study 3103245 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole (3 doses of 1 gram each at induction and 1 and 3 hours later)
Number of subjects: 108
Study 30431580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystotome-assisted prechop phacoemulsification surgery (CAPPS)
Number of subjects: 0
Study 30431580 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification surgery (CPS)
Number of subjects: 0
Study 26573010 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajust® (N = 184)
Number of subjects: 368
Study 26573010 — intervention group
Group type: COMPARATOR
Intervention: TVT-O™ (N = 184)
Number of subjects: 368
Study 25558791 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen-thawed embryo transfer (Group 2)
Number of subjects: 123
Study 25558791 — intervention group
Group type: EXPERIMENTAL
Intervention: Blastocyst transfer (Group 1)
Number of subjects: 123
Study 25558791 — intervention group
Group type: COMPARATOR
Intervention: Fresh embryo transfer (Group 3)
Number of subjects: 123
Study 24312178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (16-24 energy-% from carbohydrates)
Number of subjects: 21
Study 24312178 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (45-56 energy-% from carbohydrates)
Number of subjects: 21
Study 24312178 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet (32-35 energy-% from carbohydrates)
Number of subjects: 21
Study 22144108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic surveillance every 3 months (Gr3M)
Number of subjects: 1278
Study 22144108 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonographic surveillance every 6 months (Gr6M)
Number of subjects: 1278
Study 20010231 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier detection and proactive clinical recognition of dyspeptic signs and symptoms
Number of subjects: 0
Study 17471340 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment (twice daily for 5 days prior to surgery)
Number of subjects: 37
Study 17471340 — intervention group
Group type: COMPARATOR
Intervention: Control (no mupirocin treatment)
Number of subjects: 37
Study 12542598 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin 1 mg i.v. at 12‐h intervals (group A)
Number of subjects: 24
Study 10711411 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (4 IU/m2 per day, subcutaneous injections, every evening for 6 months)
Number of subjects: 20
Study 10711411 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 8808110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA) for 6 months
Number of subjects: 25
Study 8808110 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 25
Study 1361175 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 330
Study 1361175 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 330
Study 1361175 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 330
Study 1361175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 330
Study 1361175 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 330
Study 6148814 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis therapy
Number of subjects: 0
Study 6148814 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilators
Number of subjects: 0
Study 6148814 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin therapy
Number of subjects: 0
Study 6148814 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercises and elastic stockings
Number of subjects: 0
Study 31170994 — intervention group
Group type: EXPERIMENTAL
Intervention: AITC cough challenge (selective TRPA1 agonist)
Number of subjects: 250
Study 31170994 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cough challenge (selective TRPV1 agonist)
Number of subjects: 250
Study 31170994 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AITC and capsaicin challenges
Number of subjects: 250
Study 31170994 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics of hypersensitivity
Number of subjects: 250
Study 29106594 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol therapy (n = 21)
Number of subjects: 42
Study 29106594 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 42
Study 27041733 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide administration after pancreatic resection
Number of subjects: 0
Study 27041733 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 25150368 — intervention group
Group type: EXPERIMENTAL
Intervention: Student smoking prevention intervention (visit to an established interactive circuit)
Number of subjects: 3023
Study 25150368 — intervention group
Group type: EXPERIMENTAL
Intervention: Student smoking prevention intervention plus a parent intervention
Number of subjects: 3023
Study 25150368 — intervention group
Group type: COMPARATOR
Intervention: Control group (visit to an established exercise and nutrition interactive circuit)
Number of subjects: 3023
Study 22377745 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 10 mg/d
Number of subjects: 14
Study 22377745 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/d
Number of subjects: 14
Study 22377745 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 10 mg/d and 20 mg/d
Number of subjects: 14
Study 19297314 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 on day 1
Number of subjects: 111
Study 19297314 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2 on day 5 with oblimersen 7 mg/kg/day continuous i.v. infusion on days 1-7
Number of subjects: 111
Study 17697219 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 10 microg x ml(‐1) combined with prolonged injection (30 s) (Group IV)
Number of subjects: 200
Study 17697219 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 50 microg x ml(‐1) (Group I)
Number of subjects: 200
Study 17697219 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 25 microg x ml(‐1) (Group II)
Number of subjects: 200
Study 17697219 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 10 microg x ml(‐1) (Group III)
Number of subjects: 200
Study 15376729 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional gait data analysis technique
Number of subjects: 0
Study 11374112 — intervention group
Group type: EXPERIMENTAL
Intervention: Astrand protocol
Number of subjects: 37
Study 11374112 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruce protocol
Number of subjects: 37
Study 11374112 — intervention group
Group type: EXPERIMENTAL
Intervention: Costill/Fox protocol
Number of subjects: 37
Study 9710871 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate solution (0.7 g/kg BW/h)
Number of subjects: 0
Study 9710871 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 0
Study 9710871 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate solution plus caffeine (5 mg/kg BW)
Number of subjects: 0
Study 8279597 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR training
Number of subjects: 172
Study 3056237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (30 mg/kg)
Number of subjects: 6
Study 3056237 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (30 mg/kg)
Number of subjects: 6
Study 4881068 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin 1.0 g, 0.5 g, and 0.25 g dosages
Number of subjects: 0
Study 4881068 — intervention group
Group type: COMPARATOR
Intervention: Antrypol, Moranyl, and Naganol (brands of suramin)
Number of subjects: 0
Study 31031098 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with causal information (UC + CI)
Number of subjects: 94
Study 31031098 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 94
Study 28301561 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-minute hatha yoga practice groups twice weekly for 8 weeks
Number of subjects: 38
Study 28301561 — intervention group
Group type: COMPARATOR
Intervention: 90-minute attention control education groups twice weekly for 8 weeks
Number of subjects: 38
Study 24519034 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE+ group (vitamins A, C, E, and selenium)
Number of subjects: 126
Study 24519034 — intervention group
Group type: COMPARATOR
Intervention: ACE- group (standard ISSNHL treatment regimen only)
Number of subjects: 126
Study 24519034 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE+ group
Number of subjects: 126
Study 23754736 — intervention group
Group type: EXPERIMENTAL
Intervention: Sifalimumab administered every 14 days as a 30- to 60-minute intravenous infusion with escalating doses of 0.3, 1.0, 3.0, and 10 mg/kg.
Number of subjects: 120
Study 23754736 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dosing of sifalimumab at 200, 600, and 1,200 mg monthly (with a loading dose at Day 14).
Number of subjects: 120
Study 23754736 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic model of sifalimumab.
Number of subjects: 120
Study 21542414 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 1564
Study 21542414 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 1564
Study 21542414 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab and Zoledronic acid
Number of subjects: 1564
Study 20183195 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylmercury exposure through fish consumption
Number of subjects: 0
Study 20183195 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation (small-scale gold mining)
Number of subjects: 0
Study 20183195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 0
Study 20183195 — intervention group
Group type: COMPARATOR
Intervention: Comparison with Brazilian studies
Number of subjects: 0
Study 19442337 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0
Study 12950579 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile nickel‐titanium rotary instrument system
Number of subjects: 26
Study 12950579 — intervention group
Group type: EXPERIMENTAL
Intervention: Hero 642 nickel‐titanium rotary instrument system
Number of subjects: 26
Study 11130382 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 3260
Study 11130382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3260
Study 9414336 — intervention group
Group type: COMPARATOR
Intervention: Standard keyboard
Number of subjects: 50
Study 9414336 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative keyboard designs (e.g. split keyboard, laterally inclined halves)
Number of subjects: 50
Study 8466068 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of regular insulin (20 u) followed by a glucose infusion (500 ml 5% dextrose in water) over 15 min
Number of subjects: 40